Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNX-2401 and Pembrolizumab for Recurrent Glioblastoma (CAPTIVE)
NCT02798406Phase 2Completed
- Sponsor
- DNAtrix
- Start
- Oct 2016
- Primary completion
- Mar 2021
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
A Phase 2 trial of Ad5-D24RGD in glioblastoma (GBM), Gliosarcoma (GS), sponsored by DNAtrix. Started Oct 2016; status: completed.
02
Drugs
Ad5-D24RGD
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02798406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02798406.